Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Mar 20;29(155):200051.
doi: 10.1183/16000617.0051-2020. Print 2020 Mar 31.

Modulator treatment for people with cystic fibrosis: moving in the right direction

J Stuart Elborn  1
Affiliations
Editorial

Modulator treatment for people with cystic fibrosis: moving in the right direction

J Stuart Elborn. Eur Respir Rev. .

Abstract

As delivery of CF healthcare services evolves, it is important for respiratory clinical teams and the wider group of specialists in the MDT to understand how modulator drugs are used, the side-effects and potential for drug interactions http://bit.ly/3akQ0tK

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: J.S. Elborn has nothing to disclose.

Comment on

References

    1. Elborn JS. Cystic fibrosis. Lancet 2016; 388: 2519–2531. doi: 10.1016/S0140-6736(16)00576-6 - DOI - PubMed
    1. FDA news release . FDA approves new breakthrough therapy for cystic fibrosis. www.fda.gov/news-events/press-announcements/fda-approves-new-breakthroug... Date last updated: 21 October 2019.
    1. Elborn JS. Adult care in cystic fibrosis. Semin Respir Crit Care Med 2019; 40: 857–868. doi: 10.1055/s-0039-3400289 - DOI - PubMed
    1. Shteinberg M, Taylor-Cousar JL. Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease. Eur Respir Rev 2020; 29: 190112. - PMC - PubMed
    1. McColley SA, Konstan MW, Ramsey BW, et al. Lumacaftor/ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV(1). J Cyst Fibros 2019; 18: 94–101. doi: 10.1016/j.jcf.2018.07.011 - DOI - PMC - PubMed

MeSH terms

Substances